Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cleveland Clinic Journal of Medicine (CCJM)
Recent studies and guidelines are shifting the paradigm in coagulation management for cirrhosis patients undergoing low-risk procedures; discover why traditional markers like INR may not be reliable indicators of bleeding risk.
Gastroenterology October 4th 2023
ACP Internist
Dive into this intriguing case of a young woman presenting with right calf pain and an acute thrombosis. Join your peers in discerning the most appropriate therapeutic strategy, deepening your clinical acumen in the process.
Hematology July 12th 2023
ACP Hospitalist
The new recommendations include continuing antiplatelet therapy for patients with a baseline indication for it, starting dual antiplatelet therapy for patients with confirmed ACS, and adding prophylactic-dose LMWH for patients on antiplatelet therapy for a previous stroke.
Cardiology July 12th 2023
Guideline Central
Check out the updated guideline for changes prevention and treatment of VTE in a variety of cancer settings.
Family Medicine/General Practice May 3rd 2023
ReachMD
Because each patient reports unique challenges, there is no “one size fits all” approach to managing cancer-associated venous thrombosis (CAT). Thrombosis is a complication that HCPs are not recognizing early enough in the face of multiple options for appropriately treating and managing CAT; additionally, there is a lack of awareness of new CAT management clinical data. Although the morbidity and mortality of VTE in cancer patients remain high, unfortunately, its management is not given the same priority. And although recommendations suggest an individualized approach to managing these patients, clinical practice adoption is slow. Published guidelines and clinical trial data do not always correspond to real-world practice and prescribing practices. As a result, many existing CAT management protocols must be updated as new guidance is warranted.
Oncology, Medical April 3rd 2023
Annals of Internal Medicine
Twelve-hundred (1,200) patients admitted for 48 hours or more for COVID were randomized to 2.5mg of apixaban or placebo twice daily for 30 days. The incidence of death or thromboembolism was low and similar in the two arms of this study. The study was terminated early and the authors say the results are imprecise.
Emergency Medicine March 29th 2023